Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 117

1.

Discrepancy in Vancomycin AUC/MIC Ratio Targeted Attainment Based upon the Susceptibility Testing in Staphylococcus aureus.

Eum S, Bergsbaken RL, Harvey CL, Warren JB, Rotschafer JC.

Antibiotics (Basel). 2016 Sep 27;5(4). pii: E34.

2.

Microbiological Assessment of Polymyxin B Components Tested Alone and in Combination.

Kassamali Z, Prince RA, Danziger LH, Rotschafer JC, Rhomberg PR, Jones RN.

Antimicrob Agents Chemother. 2015 Dec;59(12):7823-5. doi: 10.1128/AAC.01021-15. Epub 2015 Sep 21.

3.

Polymyxins in 2015: it's like déjà vu all over again.

Pogue JM, Rotschafer JC.

Pharmacotherapy. 2015 Jan;35(1):9-10. doi: 10.1002/phar.1543. No abstract available.

PMID:
25630410
4.

Vancomycin: over 50 years later and still a work in progress.

Rybak MJ, Rotschafer JC, Rodvold KA.

Pharmacotherapy. 2013 Dec;33(12):1253-5. doi: 10.1002/phar.1382. No abstract available.

PMID:
24302197
5.

Reply to Nation et al.

Kassamali Z, Rotschafer JC, Jones RN, Prince RA, Danziger LH.

Clin Infect Dis. 2013 Dec;57(11):1657-8. doi: 10.1093/cid/cit525. Epub 2013 Aug 9. No abstract available.

PMID:
23934308
6.

Polymyxins: wisdom does not always come with age.

Kassamali Z, Rotschafer JC, Jones RN, Prince RA, Danziger LH.

Clin Infect Dis. 2013 Sep;57(6):877-83. doi: 10.1093/cid/cit367. Epub 2013 Jul 11. Review.

PMID:
23728146
7.

The Economic Impact of Starting, Stopping, and Restarting an Antibiotic Stewardship Program: A 14-Year Experience.

Ullman MA, Parlier GL, Warren JB, Mateo N, Harvey C, Sullivan CJ, Bergsbaken R, Mitropoulos IF, Bosso JA, Rotschafer JC.

Antibiotics (Basel). 2013 Apr 24;2(2):256-64. doi: 10.3390/antibiotics2020256.

8.

Streptococcus pneumoniae serotypes: nine-year experience at a level-one trauma center.

Elshaboury RH, Bergsbaken RL, Rotschafer JC.

Minn Med. 2012 Aug;95(8):45-7.

PMID:
22953475
9.

Optimal use of fluoroquinolones in the intensive care unit setting.

Rotschafer JC, Ullman MA, Sullivan CJ.

Crit Care Clin. 2011 Jan;27(1):95-106. doi: 10.1016/j.ccc.2010.11.005. Review.

PMID:
21144988
10.
11.
12.

Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists.

Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M, Dalovisio JR, Levine DP.

Clin Infect Dis. 2009 Aug 1;49(3):325-7. doi: 10.1086/600877. Erratum in: Clin Infect Dis. 2009 Nov 1;49(9):1465.

PMID:
19569969
13.

Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, Dalovisio JR, Levine DP.

Am J Health Syst Pharm. 2009 Jan 1;66(1):82-98. doi: 10.2146/ajhp080434. Review. No abstract available. Erratum in: Am J Health Syst Pharm. 2009 May 15;66(10):887.

PMID:
19106348
14.

Frequency of 1st- and 2nd-step topoisomerase mutations in Streptococcus pneumoniae following levofloxacin and moxifloxacin exposure.

Hovde LB, Simonson DA, Rotschafer JC.

Diagn Microbiol Infect Dis. 2008 Mar;60(3):295-9. Epub 2007 Nov 28.

PMID:
18053674
15.

In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant.

Schafer J, Hovde LB, Simonson D, Rotschafer JC.

Diagn Microbiol Infect Dis. 2008 Feb;60(2):155-61. Epub 2007 Oct 29.

PMID:
17910998
17.

Colistin methanesulfonate against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model.

Kroeger LA, Hovde LB, Mitropoulos IF, Schafer J, Rotschafer JC.

Antimicrob Agents Chemother. 2007 Sep;51(9):3431-3. Epub 2007 Jun 18.

18.

Penicillin allergy skin testing: what do we do now?

Schafer JA, Mateo N, Parlier GL, Rotschafer JC.

Pharmacotherapy. 2007 Apr;27(4):542-5. Review.

PMID:
17381381
19.

Adverse events associated with the use of oral cephalosporins/cephems.

Mitropoulos IF, Rotschafer JC, Rodvold KA.

Diagn Microbiol Infect Dis. 2007 Mar;57(3 Suppl):67S-76S. Epub 2007 Feb 9. Review.

PMID:
17292575
20.

Population pharmacokinetic modeling and Monte Carlo simulation of varying doses of intravenous metronidazole.

Sprandel KA, Drusano GL, Hecht DW, Rotschafer JC, Danziger LH, Rodvold KA.

Diagn Microbiol Infect Dis. 2006 Aug;55(4):303-9.

PMID:
16887471
21.

Consistent rates of kill of Staphylococcus aureus by gentamicin over a 6-fold clinical concentration range in an in vitro pharmacodynamic model (IVPDM).

Schafer JA, Hovde LB, Rotschafer JC.

J Antimicrob Chemother. 2006 Jul;58(1):108-11. Epub 2006 May 30.

PMID:
16735429
22.

Antimicrobial treatment of lower respiratory tract infections in the hospital setting.

Grossman RF, Rotschafer JC, Tan JS.

Am J Med. 2005 Jul;118 Suppl 7A:29S-38S. Review.

PMID:
15993675
23.

Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens.

Hermsen ED, Hovde LB, Konstantinides GN, Rotschafer JC.

Antimicrob Agents Chemother. 2005 Apr;49(4):1633-5.

25.

Dynamic analysis of peritoneal dialysis associated peritonitis.

Hotchkiss JR, Hermsen ED, Hovde LB, Simonson DA, Rotschafer JC, Crooke PS.

ASAIO J. 2004 Nov-Dec;50(6):568-76.

PMID:
15672790
26.

Pharmacodynamics of pulse dosing versus standard dosing: in vitro metronidazole activity against Bacteroides fragilis and Bacteroides thetaiotaomicron.

Ibrahim KH, Gunderson BW, Hermsen ED, Hovde LB, Rotschafer JC.

Antimicrob Agents Chemother. 2004 Nov;48(11):4195-9.

27.

The importance of bactericidal drugs: future directions in infectious disease.

Finberg RW, Moellering RC, Tally FP, Craig WA, Pankey GA, Dellinger EP, West MA, Joshi M, Linden PK, Rolston KV, Rotschafer JC, Rybak MJ.

Clin Infect Dis. 2004 Nov 1;39(9):1314-20. Epub 2004 Oct 7. Review.

PMID:
15494908
28.

Role of topoisomerase mutations and efflux in fluoroquinolone resistance of Bacteroides fragilis clinical isolates and laboratory mutants.

Ricci V, Peterson ML, Rotschafer JC, Wexler H, Piddock LJ.

Antimicrob Agents Chemother. 2004 Apr;48(4):1344-6.

29.

Polymyxins: pharmacology, pharmacokinetics, pharmacodynamics, and clinical applications.

Hermsen ED, Sullivan CJ, Rotschafer JC.

Infect Dis Clin North Am. 2003 Sep;17(3):545-62. Review.

PMID:
14711076
30.
31.

Plasmid-mediated complementation of gyrA and gyrB in fluoroquinolone-resistant Bacteroides fragilis.

Peterson ML, Rotschafer JC, Piddock LJ.

J Antimicrob Chemother. 2003 Sep;52(3):481-4. Epub 2003 Aug 13.

PMID:
12917248
32.

Mutation prevention concentration of ceftriaxone, meropenem, imipenem, and ertapenem against three strains of Streptococcus pneumoniae.

Hovde LB, Rotschafer SE, Ibrahim KH, Gunderson B, Hermsen ED, Rotschafer JC.

Diagn Microbiol Infect Dis. 2003 Apr;45(4):265-7.

PMID:
12729997
33.

Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model.

Gunderson BW, Ibrahim KH, Hovde LB, Fromm TL, Reed MD, Rotschafer JC.

Antimicrob Agents Chemother. 2003 Mar;47(3):905-9.

34.
35.

Microbiologic effectiveness of time- or concentration-based dosing strategies in Streptococcus pneumoniae.

Ibrahim KH, Hovde LB, Ross G, Gunderson B, Wright DH, Rotschafer JC.

Diagn Microbiol Infect Dis. 2002 Nov;44(3):265-71.

PMID:
12493174
36.

Comparative pharmacodynamics of three newer fluoroquinolones versus six strains of staphylococci in an in vitro model under aerobic and anaerobic conditions.

Wright DH, Gunderson BW, Hovde LB, Ross GH, Ibrahim KH, Rotschafer JC.

Antimicrob Agents Chemother. 2002 May;46(5):1561-3.

37.
38.

Pharmacodynamics of trovafloxacin and levofloxacin against Bacteroides fragilis in an in vitro pharmacodynamic model.

Peterson ML, Hovde LB, Wright DH, Brown GH, Hoang AD, Rotschafer JC.

Antimicrob Agents Chemother. 2002 Jan;46(1):203-10.

39.

What do we really know about antibiotic pharmacodynamics?

Gunderson BW, Ross GH, Ibrahim KH, Rotschafer JC.

Pharmacotherapy. 2001 Nov;21(11 Pt 2):302S-318S. Review.

PMID:
11714222
40.

Comparison of once-daily versus twice-daily administration of cefdinir against typical bacterial respiratory tract pathogens.

Ross GH, Hovde LB, Ibrahim KH, Ibrahim YH, Rotschafer JC.

Antimicrob Agents Chemother. 2001 Oct;45(10):2936-8.

41.

Fluoroquinolone resistance in anaerobic bacteria following exposure to levofloxacin, trovafloxacin, and sparfloxacin in an in vitro pharmacodynamic model.

Ross GH, Wright DH, Hovde LB, Peterson ML, Rotschafer JC.

Antimicrob Agents Chemother. 2001 Jul;45(7):2136-40.

42.

Intensive care unit antimicrobial resistance and the role of the pharmacist.

Ibrahim KH, Gunderson B, Rotschafer JC.

Crit Care Med. 2001 Apr;29(4 Suppl):N108-13. Review.

PMID:
11292885
43.

Application of fluoroquinolone pharmacodynamics.

Wright DH, Brown GH, Peterson ML, Rotschafer JC.

J Antimicrob Chemother. 2000 Nov;46(5):669-83. Review.

PMID:
11062185
44.

Single daily dosing of aminoglycosides--A community standard?

Brown GH, Bertino JS Jr, Rotschafer JC.

Clin Infect Dis. 2000 Mar;30(3):440-1. No abstract available.

PMID:
10722425
45.

Decreased in vitro fluoroquinolone concentrations after admixture with an enteral feeding formulation.

Wright DH, Pietz SL, Konstantinides FN, Rotschafer JC.

JPEN J Parenter Enteral Nutr. 2000 Jan-Feb;24(1):42-8.

PMID:
10638471
46.

A randomized comparison of the safety and efficacy of once-daily gentamicin or thrice-daily gentamicin in combination with ticarcillin-clavulanate.

Bertino JS Jr, Nafziger AN, Rotschafer JC.

Am J Med. 1999 Sep;107(3):296-8. No abstract available.

PMID:
10492331
47.

Fluoroquinolone resistance in Bacteroides fragilis following sparfloxacin exposure.

Peterson ML, Hovde LB, Wright DH, Hoang AD, Raddatz JK, Boysen PJ, Rotschafer JC.

Antimicrob Agents Chemother. 1999 Sep;43(9):2251-5.

48.

Implications of vancomycin degradation products on therapeutic drug monitoring in patients with end-stage renal disease.

Somerville AL, Wright DH, Rotschafer JC.

Pharmacotherapy. 1999 Jun;19(6):702-7. Review.

PMID:
10391415
49.

Bacillus anthracis: medical issues of biologic warfare.

Ibrahim KH, Brown G, Wright DH, Rotschafer JC.

Pharmacotherapy. 1999 Jun;19(6):690-701. Review.

PMID:
10391414
50.

Gram-positive infections: pharmacy issues and strategy for quinupristin/dalfopristin.

Rotschafer JC, Wright DH, Brown GH.

Diagn Microbiol Infect Dis. 1999 Feb;33(2):95-9. Review.

PMID:
10091032

Supplemental Content

Loading ...
Support Center